Quantification of PKC family genes in sporadic breast cancer by qRT-PCR: Evidence that PKCi/λ overexpression is an independent prognostic factor

International Journal of Cancer

Volumn 131, Issue 12, 2012, Pages 2852-2862

  Awadelkarim, Khalid Dafaallah ^a   Callens, Céline ^b   Rossé, Carine ^b,c   Susini, Aurélie ^b   Vacher, Sophie ^b   Rouleau, Etienne ^b   Lidereau, Rosette ^b   Bièche, Ivan ^b  

^a UNIVERSITY OF GEZIRA   (Sudan)

^b INSTITUT CURIE   (France)

^c CNRS   (France)

Author keywords

breast cancer; PKC family gene expression; prognostic significance; quantitative real time RT PCR

Indexed keywords

MESSENGER RNA; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ETA; PROTEIN KINASE C IOTA; PROTEIN KINASE C LAMBDA; PROTEIN KINASE C ZETA; PROTEIN KINASE C;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PKC BETA GENE; PKC DELTA GENE; PKC EPSILON GENE; PKC ETA GENE; PKC IOTA GENE; PKC LAMBDA GENE; PKC ZETA GENE; PKN1 GENE; PKN2 GENE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GENE; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MULTIGENE FAMILY; PROGNOSIS; PROTEIN KINASE C; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84867867576     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27600     Document Type: Article

References (49)

1. Griner EM, Kazanietz MG,. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer 2007; 7: 281-94.
2. Mackay HJ, Twelves CJ,. Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 2007; 7: 554-62.
3. 2+-dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors. Int J Cancer 1987; 40: 344-8.
4. 2+-dependent protein kinase in human breast cancer cells. Int J Cancer 1986; 37: 731-7.
5. O'Brian C, Vogel VG, Singletary SE, et al. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue. Cancer Res 1989; 49: 3215-7.
6. Gordge PC, Hulme MJ, Clegg RA, et al. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur J Cancer 1996; 32A: 2120-6.
7. Ways DK, Kukoly CA, deVente J, et al. MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 1995; 95: 1906-15.
8. Tonetti DA, Chisamore MJ, Grdina W, et al. Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines. Br J Cancer 2000; 83: 782-91.
9. Lahn M, Kohler G, Sundell K, et al. Protein kinase C alpha expression in breast and ovarian cancer. Oncology 2004; 67: 1-10.
10. Tan M, Li P, Sun M, et al. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors. Oncogene 2006; 25: 3286-95.
11. Kerfoot C, Huang W, Rotenberg SA,. Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha. J Histochem Cytochem 2004; 52: 419-22.
12. Ainsworth PD, Winstanley JH, Pearson JM, et al. Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma. Eur J Cancer 2004; 40: 2269-73.
13. Lonne GK, Cornmark L, Zahirovic IO, et al. PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer 2010; 9: 76.
14. Suzuki A, Yamanaka T, Hirose T, et al. Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures. J Cell Biol 2001; 152: 1183-96.
15. O'Brian CA, Liskamp RM, Solomon DH, et al. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985; 45: 2462-5.
16. Short MD, Fox SM, Lam CF, et al. Protein kinase Czeta attenuates hypoxia-induced proliferation of fibroblasts by regulating MAP kinase phosphatase-1 expression. Mol Biol Cell 2006; 17: 1995-2008.
17. Pan Q, Bao LW, Kleer CG, et al. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res 2005; 65: 8366-71.
18. Bieche I, Onody P, Laurendeau I, et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999; 45: 1148-56.
19. Bieche I, Parfait B, Laurendeau I, et al. Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene 2001; 20: 8109-15.
20. Finak G, Sadekova S, Pepin F, et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. Breast Cancer Res 2006; 8: R58.
21. Chomczynski P, Sacchi N,. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
22. Bieche I, Parfait B, Le Doussal V, et al. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res 2001; 61: 1652-8.
23. Didier G, Brezellec P, Remy E, et al. GeneANOVA-gene expression analysis of variance. Bioinformatics 2002; 18: 490-1.
24. Bieche I, Nogues C, Lidereau R,. Overexpression of BRCA2 gene in sporadic breast tumours. Oncogene 1999; 18: 5232-8.
25. Bieche I, Onody P, Tozlu S, et al. Prognostic value of ERBB family mRNA expression in breast carcinomas. Int J Cancer 2003; 106: 758-65.
26. Meseure D, Vacher S, Alsibai KD, et al. Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: a candidate biomarker to predict EGFR inhibitor effectiveness. Int J Cancer 2011;doi: 10.1002/ijc.26434.
27. Cizkova M, Susini A, Vacher S, et al. PIK3CA mutation impact on survival in breast cancer patients and in ERalpha, PR and ERBB2-based subgroups. Breast Cancer Res 2012; 14: R28.
28. Jackson DN, Foster DA,. The enigmatic protein kinase Cdelta: complex roles in cell proliferation and survival. FASEB J 2004; 18: 627-36.
29. Yokoyama G, Fujii T, Tayama K, et al. PKCdelta and MAPK mediate G(1) arrest induced by PMA in SKBR-3 breast cancer cells. Biochem Biophys Res Commun 2005; 327: 720-6.
30. Kanashiro CA, Khalil RA,. Signal transduction by protein kinase C in mammalian cells. Clin Exp Pharmacol Physiol 1998; 25: 974-85.
31. Saito N, Shirai Y,. Protein kinase C gamma (PKC gamma): function of neuron specific isotype. J Biochem 2002; 132: 683-7.
32. Lu D, Huang J, Basu A,. Protein kinase Cepsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death. J Biol Chem 2006; 281: 22799-807.
33. Kojima Y, Akimoto K, Nagashima Y, et al. The overexpression and altered localization of the atypical protein kinase C lambda/iota in breast cancer correlates with the pathologic type of these tumors. Hum Pathol 2008; 39: 824-31.
34. Assender JW, Gee JM, Lewis I, et al. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. J Clin Pathol 2007; 60: 1216-21.
35. McKiernan E, O'Brien K, Grebenchtchikov N, et al. Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA. Br J Cancer 2008; 99: 1644-50.
36. Masso-Welch PA, Winston JS, Edge S, et al. Altered expression and localization of PKC eta in human breast tumors. Breast Cancer Res Treat 2001; 68: 211-23.
37. Marmor MD, Skaria KB, Yarden Y,. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004; 58: 903-13.
38. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
39. Whyte J, Thornton L, McNally S, et al. PKCzeta regulates cell polarisation and proliferation restriction during mammary acinus formation. J Cell Sci 2010; 123: 3316-28.
40. Beck J, Bohnet B, Brugger D, et al. Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression. Br J Cancer 1998; 77: 87-91.
41. Stewart JR, O'Brian CA,. Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells. Mol Cancer Ther 2005; 4: 726-32.
42. Stapleton G, Malliri A, Ozanne BW,. Downregulated AP-1 activity is associated with inhibition of Protein-Kinase-C-dependent CD44 and ezrin localisation and upregulation of PKC theta in A431 cells. J Cell Sci 2002; 115: 2713-24.
43. Akimoto K, Takahashi R, Moriya S, et al. EGF or PDGF receptors activate atypical PKClambda through phosphatidylinositol 3-kinase. EMBO J 1996; 15: 788-98.
44. Sanz L, Sanchez P, Lallena MJ, et al. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J 1999; 18: 3044-53.
45. Suzuki A, Akimoto K, Ohno S,. Protein kinase C lambda/iota (PKClambda/iota): a PKC isotype essential for the development of multicellular organisms. J Biochem 2003; 133: 9-16.
46. Regala RP, Davis RK, Kunz A, et al. Atypical protein kinase C{iota} is required for bronchioalveolar stem cell expansion and lung tumorigenesis. Cancer Res 2009; 69: 7603-11.
47. Regala RP, Weems C, Jamieson L, et al. Atypical protein kinase Ciota plays a critical role in human lung cancer cell growth and tumorigenicity. J Biol Chem 2005; 280: 31109-15.
48. Regala RP, Weems C, Jamieson L, et al. Atypical protein kinase C iota is an oncogene in human non-small cell lung cancer. Cancer Res 2005; 65: 8905-11.
49. Zhang L, Huang J, Yang N, et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 2006; 66: 4627-35.